BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 13:55
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:11
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:42
  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a finger prick imageJuly 11 2018

Direct oral anticoagulants (DOACs) have been associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin. 

Researchers at the University of Nottingham have found apixaban “to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Rivaroxaban and low dose apixaban were, however, associated with increased risks of all-cause mortality compared with warfarin.”

The observational study looked at patient records from 132 231 warfarin, 7744 dabigatran, 37 863 rivaroxaban, and 18 223 apixaban users. It divided the data into whether atrial fibrillation was present or not, and looked at the risks of bleeding, ischaemic stroke, venous thromboembolism, and all-cause mortality. 

In patients with atrial fibrillation, compared with warfarin:

  • apixaban was associated with a decreased risk of major bleeding (adjusted hazard ratio 0.66) and intracranial bleeding (0.40);
  • dabigatran was associated with a decreased risk of intracranial bleeding (0.45);
  • an increased risk of all-cause mortality was associated with rivaroxaban (1.19) or on lower doses of apixaban (1.27).

In patients without atrial fibrillation, compared with warfarin:

  • apixaban was associated with a decreased risk of major bleeding (0.60), any gastrointestinal bleeding (0.55), and upper GI bleeding (0.55);
  • rivaroxaban was associated with a decreased risk of intracranial bleeding (0.54);
  • an increased risk of all-cause mortality was observed with rivaroxaban (1.51) and lower doses of apixaban (1.34).

“The findings, published in the BMJ, provide initial reassurance about the safety of DOACs as an alternative to warfarin for all new patients,” said the University.

“For many years, warfarin has been the main treatment for potentially fatal blood clots, known as venous thromboembolism (VTE). But DOACs are increasingly being used as an alternative to warfarin because patients don’t need regular tests to check if they have the right amount of drug in their bloodstream.”

Links:
University of Nottingham announcement          
Y Vinogradova et al. ‘Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care’. BMJ 2018;362:k2505           

Clinical News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...